Evidence mapPaperPMID 39092347Full record

ReviewCureus2024

Meldonium Supplementation in Professional Athletes: Career Destroyer or Lifesaver?

Amalia Pușcaș, Mădălina-Georgiana Buț, Camil-Eugen Vari, Bianca-Eugenia Ősz, Ruxandra Ștefănescu, Cristina Filip, George Jîtcă, Tudor-Ionuț Istrate, Amelia Tero-Vescan

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amalia PușcașBiochemistry, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Mădălina-Georgiana BuțBiochemistry, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Camil-Eugen VariPharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Bianca-Eugenia ŐszPharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Ruxandra ȘtefănescuPharmacognosy and Phytotherapy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Cristina FilipBiochemistry, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
George JîtcăPharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Tudor-Ionuț IstrateBiochemistry, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.
Amelia Tero-VescanBiochemistry, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, ROU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meldonium is a substance with known anti-anginal effects demonstrated by numerous studies and human clinical trials; however, it does not possess marketing authorization within the European Union, only in ex-Soviet republics. Since 2016, meldonium has been included by the World Anti-doping Agency (WADA) on the S4 list of metabolic modulators. In performance athletes, meldonium is now considered a doping agent due to its capacity to decrease lactate production during and after exercise, its capability to enhance the storage and utilization of glycogen, and its protective action against oxidative stress. Together, these attributes can significantly improve aerobic endurance, cardiac function, and capacity as well as shorten recovery times (allowing higher intensity training), thereby enhancing performance. The purpose of this review is to highlight the most important mechanisms underlying the protective effect of meldonium against mitochondrial dysfunction (MD), which is responsible for oxidative stress, inflammation, and the cardiac changes known as "athletic heart syndrome." Meldonium acts as an inhibitor of γ-butyrobetaine hydroxylase (BBOX), preventing the de novo synthesis of carnitine and its absorption at the intestinal level via the organic cation/carnitine transporter 2 (OCTN2) and directing the oxidation of fatty acids to the peroxisomes. The decrease in mitochondrial β-oxidation of fatty acids leads to a reduction in lipid peroxidation products that cause oxidative stress and prevent the formation of acyl/acetyl-carnitines involved in numerous pathological disorders. Given the recent findings of the potentially detrimental effects of prolonged high-intensity exercise on cardiovascular health and coronary atherosclerosis, there may be legitimate arguments for the justification of the use of substances like meldonium as protective supplements for athletes.

Indexed as

carnitine inhibitordopingmeldoniummetabolic modulatorsperformance athletes

Identifiers

PMID39092347
PMCPMC11292090

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.